Amylyx Pharmaceuticals Investor Presentation 2023

Amylyx Pharmaceuticals presented their November 2023 investor update covering RELYVRIO (AMX0035), the first FDA-approved ALS therapy demonstrating benefit on function and survival. The presentation highlights the product's strong U.S. and Canadian launch with approximately 3,900 patients enrolled and $272.3M revenue in the first three quarters, along with ongoing clinical evaluation in other neurodegenerative diseases including Progressive Supranuclear Palsy and Wolfram syndrome.